News

Cognizant will extend its existing relationship with Merck, dating back to 2005, to become a key technology partner and provide a full suite of services encompassing applications outsourcing,

The primary endpoint of the study is the objective tumor response or lack of early disease progression. The trial is expected to enroll approximately 30 patients at a

The antibody was developed using Medarex’s UltiMAb technology and is the fifth UltiMAb-derived antibody in clinical development by Amgen, including two UltiMAb antibodies in Phase II clinical studies.

Bystolic is a once-daily medication that can be used alone or in combination with other hypertension treatments. Forest licensed US and Canadian rights to Bystolic (nebivolol) from Mylan

The supplemental biological license application (sBLA) was submitted by Bristol-Myers Squibb Company to meet expected long-term demand for Orencia. Jung-Jin Seo, chairman and CEO of Celltrion, said: “We

Innocoll plans to study CollaRx gentamicin topical for the treatment of diabetic foot infections of varying severity in a series of Phase II trials and has appointed the

The ANDES (AGI-1067 as a novel antidiabetic agent evaluation study) trial has enrolled 999 patients with type II diabetes at approximately 150 clinical sites in the US, South

A-001 is currently being evaluated for acute chest syndrome in a Phase II clinical trial in the US called IMPACTS (investigation of the modulation of phospholipase in acute

The results showed that a single dose of ABthrax, administered without concomitant antibiotics, improved survival rates by up to 64% when administered after animals were symptomatic for anthrax